REGULATABLE FUSION PROMOTERS

• US 20090053295A1
• Filed: 09/29/2006
• Published: 02/26/2009
• Est. Priority Date: 10/01/2005
• Status: Abandoned Application

• Current Assignee: Charles Stout
• Original Assignee: Charles Stout
• Inventors: Stout, Charles
• Application Number:
  US12/088,921
• Publication Number:
  US 20090053295A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Abstract

Fusion promoters are described that combine a RNA polymerase III basal promoter and regulatory elements from RNA polymerase II regulatory regions, and which provide specific regulation of expression from the promoter. Such fusion promoters are useful, for example, for expressing RNAi agents in vivo.

Claims

1. A nucleic acid construct comprising a Pol III/Pol II fusion promoter comprising

an RNA Polymerase III-binding basal promoter region;

and

cis-acting regulatory regions from a Pol II promoter, operably linked with said basal promoter region;

wherein said cis-acting regulatory regions provide specific regulation of expression from said construct.

2. The construct of claim 1, wherein said cis-acting regulatory regions provide cell-specific regulation, tissue-specific regulation, cell-cycle specific regulation, tumor-specific regulation in vivo, radiation-induced expression in vivo, or estrogen-induced expression in vivo.

8. The construct of claim 1, wherein said construct further comprises a sequence encoding a shRNA, a siRNA, or an RNAi agent targeting an mRNA of a disease-associated gene, wherein said sequence is operably linked with said fusion promoter.

10. The construct of claim 1, wherein said basal promoter region is selected from the group consisting of a Pol III basal promoter, a U6 basal promoter, a H1 basal promoter, a tRNA basal promoter, and a mutated Pol II basal promoter, wherein said mutated Pol II basal promoter preferentially binds Pol III instead of Pol II.

15. The construct of claim 1, wherein said Pol II cis-acting regulatory regions comprise CMV early intermediate regulatory regions or a complete Pol II regulatory region less the basal promoter.

56. A pharmaceutical composition comprising a nucleic acid construct of claim 1, wherein said nucleic acid construct further comprises a shRNA or siRNA sequence operatively linked with said fusion promoter;

and

a pharmaceutically acceptable carrier or excipient.

57. The pharmaceutical composition of claim 56, wherein said composition is formulated as an injectable composition, a composition for topical administration, or a liposomal composition.

60. The pharmaceutical composition of claim 56, wherein said composition comprises a viral vector.

3-7. -7. (canceled)

9. (canceled)

11-14. -14. (canceled)

16-17. -17. (canceled)

18. A vector comprising a Pol III/Pol II fusion promoter comprising

a RNA Polymerase III-binding basal promoter region;

and

cis-acting regulatory regions from a Pol II promoter operably linked with said basal promoter region;

wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter.

19. The vector of claim 18, further comprising a sequence encoding an RNAi agent, a siRNA, or a shRNA, wherein said sequence is operably linked with said fusion promoter.

22. The vector of claim 18, wherein said vector is selected from the group consisting of a plasmid, a viral-based vector, a replication defective vector, and a replication competent vector.

20-21. -21. (canceled)

23-25. -25. (canceled)

26. A cell comprising a Pol III/Pol II fusion promoter operably linked with a coding sequence, wherein said fusion promoter comprises

a RNA Polymerase III-binding basal promoter region;

and

cis-acting regulatory regions from a Pol II promoter operably linked with said basal promoter region;

wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter.

27. The cell of claim 26, wherein said coding sequence encodes an RNAi agent, a siRNA, or a shRNA.

30. The cell of claim 27, wherein said fusion promoter and said RNAi agent are in a vector.

31. The cell of claim 30, wherein said vector is a plasmid or a viral vector.

33. The cell of claim 26, wherein said cell is in cell culture.

34. The cell of claim 33, wherein said cell is selected from the group consisting of an animal cell, a human cell, an insect cell, and a plant cell.

38. The cell of claim 26, wherein said cell is in an animal, a plant, or a fungus.

39. The cell of claim 38, wherein said animal is selected from the group consisting of a human, a bovine, a porcine, an ovine, a feline, a canine, and a bird.

28-29. -29. (canceled)

32. (canceled)

35-37. -37. (canceled)

40-47. -47. (canceled)

48. A non-human transgenic organism, comprising

a plurality of cells comprising a genetic construct comprising a Pol III/Pol II fusion promoter operably linked with a coding sequence, wherein said Pol III/Pol II fusion promoter comprises

a RNA Polymerase III-binding basal promoter region;

and

cis-acting regulatory regions from a Pol II promoter operably linked with said basal promoter region;

wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter.

49. The organism of claim 48, wherein said coding sequence encodes an RNAi agent.

50. The organism of claim 48, wherein said organism is an animal or a plant.

51-55. -55. (canceled)

58-59. -59. (canceled)

61-64. -64. (canceled)

65. A method for expressing an RNAi agent in a cell, comprising

maintaining a cell under expression conditions, wherein said cell comprises a genetic construct comprising a Pol III/Pol II fusion promoter operably linked with a RNAi agent encoding sequence, wherein said Pol III/Pol II fusion promoter comprises

a RNA Polymerase III-binding basal promoter region;

and

cis-acting regulatory regions from a Pol II promoter, operably linked with said basal promoter region;

wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter.

66. The method of claim 65, wherein said RNAi agent is an shRNA or an siRNA.

67. (canceled)

68. A method for inhibiting expression of a target gene in a cell, comprising

transfecting said cell with a vector comprising a genetic construct, wherein said construct comprises a Pol III/Pol II fusion promoter operably linked with a nucleic acid sequence encoding an RNAi agent targeted to said target gene, wherein said fusion promoter comprises

a RNA Polymerase III-binding basal promoter region;

and cis-acting regulatory regions from a Pol II promoter, operably linked with said basal promoter region, wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter; and

maintaining said cell under expression conditions.

69. The method of claim 68, wherein said cell is in an organism.

70. The method of claim 68, wherein said construct comprises a regulatory element selected from the group consisting of a tissue-specific regulatory element and a tumor-specific regulatory element wherein said target gene is preferentially inhibited in said cell corresponding to said regulatory element.

72. The method of claim 68, wherein said inhibition is induced in response to radiation, the presence of an effective amount of a non-peptide and non-nucleotidic chemical species, or an estrogen.

71. (canceled)

73-79. -79. (canceled)

80. A method for validating a target as a therapeutic target, comprising

inhibiting expression of a putative therapeutic target gene in said cell, wherein said inhibiting is due to expression of an RNAi agent from a genetic construct comprising a Pol III/Pol II fusion promoter operably linked with a nucleic acid sequence encoding said RNAi agent, wherein said fusion promoter comprises a RNA Polymerase III-binding basal promoter region;

and cis-acting regulatory regions from a Pol II promoter operably linked with said basal promoter region, wherein said cis-acting regulatory regions allow specific regulation of expression from said fusion promoter; and

determining whether a biological change in said cell following said inhibiting corresponds with a therapeutic effect, wherein correspondence of said biological change with said therapeutic effect is indicative that said gene is a therapeutic target gene.

81-83. -83. (canceled)

84. A method for treating a disease or condition wherein inhibition of a target gene provides a beneficial effect, comprising

administering a pharmacologically effective amount of a vector comprising a genetic construct comprising a Pol III/Pol II fusion promoter providing specific regulation of expression, operably linked with a sequence encoding an RNAi agent, to a subject suffering from or at risk of said disease or condition,

wherein said fusion promoter comprises a RNA Polymerase III-binding basal promoter region;

and cis-acting regulatory regions from a Pol II promoter operably linked with said basal promoter region, wherein said cis-acting regulatory regions provide specific regulation of expression from said fusion promoter.

85. The method of claim 84, wherein said vector is a plasmid or a viral vector.

87. The method of claim 84, wherein said subject is selected from the group consisting of a human, a non-human animal, and a plant.

90. The method of claim 84, wherein said RNAi agent is an shRNA or an siRNA.

86. (canceled)

88-89. -89. (canceled)

91-101. -101. (canceled)